Serendipitous findings by scientists in Belgium, France, and Canada point to a new potential therapeutic target for type 2 diabetes: a gene called SHIP2 that appears to act as a brake on insulin production. The report appears in the January 4 issue of Nature.
The investigators found that genetically engineered newborn mice that lacked copies of the SHIP2 gene showed signs of hypoglycemia—they were blue or pale, lethargic, showed signs of respiratory distress, and failed to gain weight—and died within 3 days of birth. Further study revealed that the mice were hypoglycemic because of hypersensitivity to insulin rather than overproduction of the hormone.
Stephenson J. New Insulin Regulation Finding. JAMA. 2001;285(6):725. doi:10.1001/jama.285.6.725
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: